Updated

Science Corporation, led by Neuralink co-founder Max Hodak, announced it has implanted its PRIMA vision-restoring chip in its first patient with Stargardt disease, a hereditary condition that causes progressive vision loss. Hodak discussed the milestone on stage at TechCrunch Disrupt, framing it as a step toward the company's broader goal of developing a novel brain-computer interface. The procedure represents a significant medical and commercial milestone for Science Corporation, which has positioned PRIMA as a bridge technology linking retinal implants to more advanced neural interface systems. Success in Stargardt patients could pave the way for wider application of the chip in treating other forms of vision impairment.